These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 17307249)

  • 21. Adoptive cancer immunotherapy using genetically engineered designer T-cells: First steps into the clinic.
    Eshhar Z
    Curr Opin Mol Ther; 2010 Feb; 12(1):55-63. PubMed ID: 20140817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing.
    Govers C; Sebestyén Z; Coccoris M; Willemsen RA; Debets R
    Trends Mol Med; 2010 Feb; 16(2):77-87. PubMed ID: 20122868
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T-cell engineering for cancer immunotherapy.
    Sadelain M
    Cancer J; 2009; 15(6):451-5. PubMed ID: 20010162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical development of T cell receptor gene therapy.
    Bendle GM; Haanen JB; Schumacher TN
    Curr Opin Immunol; 2009 Apr; 21(2):209-14. PubMed ID: 19321326
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generation of tumor-specific T-cell therapies.
    Morris E; Hart D; Gao L; Tsallios A; Xue SA; Stauss H
    Blood Rev; 2006 Mar; 20(2):61-9. PubMed ID: 15978709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene.
    Lamers CH; van Elzakker P; Langeveld SC; Sleijfer S; Gratama JW
    Cytotherapy; 2006; 8(6):542-53. PubMed ID: 17148030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
    Riquelme E; Carreño LJ; González PA; Kalergis AM
    Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene-engineered varicella-zoster virus reactive CD4+ cytotoxic T cells exert tumor-specific effector function.
    Landmeier S; Altvater B; Pscherer S; Eing BR; Kuehn J; Rooney CM; Juergens H; Rossig C
    Cancer Res; 2007 Sep; 67(17):8335-43. PubMed ID: 17804749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
    Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
    Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploiting T cell receptor genes for cancer immunotherapy.
    Xue S; Gillmore R; Downs A; Tsallios A; Holler A; Gao L; Wong V; Morris E; Stauss HJ
    Clin Exp Immunol; 2005 Feb; 139(2):167-72. PubMed ID: 15654813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CMV-specific TCR-transgenic T cells for immunotherapy.
    Schub A; Schuster IG; Hammerschmidt W; Moosmann A
    J Immunol; 2009 Nov; 183(10):6819-30. PubMed ID: 19864595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sustained antigen-specific antitumor recall response mediated by gene-modified CD4+ T helper-1 and CD8+ T cells.
    Moeller M; Kershaw MH; Cameron R; Westwood JA; Trapani JA; Smyth MJ; Darcy PK
    Cancer Res; 2007 Dec; 67(23):11428-37. PubMed ID: 18056471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid analysis of T-cell selection in vivo using T cell-receptor retrogenic mice.
    Holst J; Vignali KM; Burton AR; Vignali DA
    Nat Methods; 2006 Mar; 3(3):191-7. PubMed ID: 16489336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetically modulating T-cell function to target cancer.
    Merhavi-Shoham E; Haga-Friedman A; Cohen CJ
    Semin Cancer Biol; 2012 Feb; 22(1):14-22. PubMed ID: 22210183
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells.
    Scholten KB; Kramer D; Kueter EW; Graf M; Schoedl T; Meijer CJ; Schreurs MW; Hooijberg E
    Clin Immunol; 2006 May; 119(2):135-45. PubMed ID: 16458072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced T cell receptor gene therapy for cancer.
    Kieback E; Uckert W
    Expert Opin Biol Ther; 2010 May; 10(5):749-62. PubMed ID: 20201709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The T-body approach: redirecting T cells with antibody specificity.
    Eshhar Z
    Handb Exp Pharmacol; 2008; (181):329-42. PubMed ID: 18071952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multi-cistronic vector encoding optimized safety switch for adoptive therapy with T-cell receptor-modified T cells.
    van Loenen MM; de Boer R; Hagedoorn RS; Jankipersadsing V; Amir AL; Falkenburg JH; Heemskerk MH
    Gene Ther; 2013 Aug; 20(8):861-7. PubMed ID: 23364317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lentiviral vector gene transfer into human T cells.
    Verhoeyen E; Costa C; Cosset FL
    Methods Mol Biol; 2009; 506():97-114. PubMed ID: 19110622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy with TCR-redirected T cells: comparison of TCR-transduced and TCR-engineered hematopoietic stem cell-derived T cells.
    Stärck L; Popp K; Pircher H; Uckert W
    J Immunol; 2014 Jan; 192(1):206-13. PubMed ID: 24293634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.